MRNA - Moderna, Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $46.50 DETAILS

Stock News

Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout

Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.

Jul 10, 2026 08:04 AM • 247wallst.com

Moderna wins EU contract for RSV vaccine supply

Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial virus vaccine ‌to six countries in the region.

Jul 09, 2026 03:17 AM • reuters.com

Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026

CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.

Jul 09, 2026 03:00 AM • accessnewswire.com

Moderna Appoints Michael McDonnell to Board of Directors

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience CAMBRIDGE, MA / ACCESS Newswire / July 8, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the appointment of Michael McDonnell to its Board of Directors, effective July 8, 2026. Mr. McDonnell will also serve on the Board's Audit Committee.

Jul 08, 2026 03:00 AM • accessnewswire.com

Moderna Stock Is Soaring. Is It Too Late to Buy?

Moderna is no longer just a COVID-19 vaccine company. A growing pipeline could fuel long-term revenue growth.

Jul 07, 2026 01:15 AM • fool.com

Moderna (MRNA) Outpaces Stock Market Gains: What You Should Know

Moderna (MRNA) closed at $81.76 in the latest trading session, marking a +2.51% move from the prior day.

Jul 06, 2026 02:50 PM • zacks.com

These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More

Each of these biotech players has reached an important turning point. Recent drug approvals could supercharge the performance of one in particular.

Jul 06, 2026 02:10 PM • fool.com

2 More Stocks to Buy for the AI Convergence

Tom Yeung here with your Sunday Digest . In the days following its IPO, Space Exploration Technologies Corp. ( SPCX ) surged 25%, rewarding early investors and turning its owner, Elon Musk, into a trillionaire.

Jul 05, 2026 08:00 AM • investorplace.com

Moderna Is Up More Than 70% in a Month After a 9-0 FDA Vote. Wall Street's Average Price Target Says It Should Fall 44%.

An FDA advisory panel voted 9-0 that Moderna's mRNA flu vaccine's benefits outweigh its risks. A final approval decision is expected by Aug. 5.

Jul 03, 2026 09:07 AM • fool.com

MRNA Stock on the Move: What Sparked the 33.5% Jump in the Past Week?

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Jul 03, 2026 08:35 AM • zacks.com

Moderna vs. Recursion: Which Cutting-Edge Pharma Stock Is a Better Buy in 2026?

Moderna is evolving from a COVID-19 vaccine specialist into a multi-product firm with major oncology and rare disease partnerships. Recursion Pharmaceuticals is leveraging artificial intelligence and massive biological datasets to accelerate drug discovery via high-tech collaborations.

Jul 03, 2026 07:14 AM • fool.com

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

Arcutis doubled revenue last year while Vertex delivered strong profits and cash flow. Explore how each company stacks up on growth, risk, and value.

Jul 03, 2026 04:37 AM • fool.com

Moderna stock jumps as pipeline progress and flu shot data lift sentiment

Moderna Inc. (MRNA) shares rose 9.2% on Thursday, making the biotechnology company among the top performers in the S&P 500 as investors responded positively to new pipeline updates, encouraging influenza vaccine data, and favorable analyst commentary. The stock extended its recent rally after climbing to a new annual high on Wednesday.

Jul 02, 2026 11:51 AM • invezz.com

Short Squeeze Alert—Moderna Stock Surges on New Strategy

At that time, Moderna revealed its strategy for using mRNA to combat cancer and rare diseases. It's a move beyond vaccines, and investors seem to like it.

Jul 01, 2026 03:00 AM • marketbeat.com

Is Moderna Stock a No-Brainer Buy After a Key FDA Win?

On June 16, Moderna announced major news regarding one of its most highly anticipated follow-up products: an mRNA-based flu vaccine. The biotech company has also made some other promising announcements in recent weeks.

Jun 30, 2026 10:15 AM • fool.com

MRNA Stock Jumps to 52-Week High on Expansion Plans Beyond Vaccines

Moderna hit a 52-week high after it unveiled a strategy to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and AI-driven R&D.

Jun 29, 2026 10:06 AM • zacks.com

Stock Of The Day: Will The Moderna Rally Continue?

Moderna, Inc. (NASDAQ:MRNA) shares are trading higher on Monday. This follows Friday's gain of more than 12%.

Jun 29, 2026 06:03 AM • benzinga.com

Moderna stock soars as cancer pipeline and CAR-T push ignite optimism

Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company's Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and build a diversified portfolio spanning oncology, autoimmune diseases, and next-generation mRNA therapies.

Jun 26, 2026 10:47 AM • invezz.com

Moderna Is Up 13% Today: Is It Outperforming Other Vaccine Stocks Like Merck and Pfizer?

Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a remarkable run for the mRNA pioneer.

Jun 26, 2026 08:01 AM • 247wallst.com